Latest Breaking News On - Genome institute of singapore - Page 18 : vimarsana.com

Boehringer Ingelheim: BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES

Boehringer Ingelheim gains exclusive global rights to a panel of cancer-specific antibodies to enable the development of targeted cancer therapies These engineered antibodies may allow for

Reinhard malinDamian oconnellCliver woodAgency for scienceInnovation unit communicationsBoehringer ingelheimGenome institute of singaporeExperimental drug development centreSingapore gastric cancer consortiumCorporate communicationsInstitute of bioengineering bioimagingCorporate affairsAntibody drug conjugateSenior corporate vice presidentGlobal headDiscovery research

acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.

Boehringer ingelheimReinhard malinEngagers tcesDamian oconnellCliver woodAgency for scienceInnovation unit communicationsResearch partnersTechnology organisationExperimental drug development centreGenome institute of singaporeSingapore gastric cancer consortiumCorporate communicationsAnimal healthInstitute of bioengineering bioimagingCorporate affairs

Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies

Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies
jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.

Rheinland pfalzReinhard malinEngagers tcesBiophotonics bioimagingDamian oconnellCliver woodAgency for scienceInnovation unit communicationsResearch partnersBoehringer ingelheimTechnology organisationExperimental drug development centreGenome institute of singaporeSingapore gastric cancer consortiumExperimental biotherapeutics centreExperimental therapeutics centre

A*STAR, NHCS, NUS, and Novo Nordisk to Collaborate on Cardiovascular Disease Research

A*STAR, NHCS, NUS, and Novo Nordisk to Collaborate on Cardiovascular Disease Research
dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.

National university of singaporeSingapore generalRoger fooMark richardsKarin conde knapeChromatin organisationAgency for scienceNational heart centre singaporeFounding programme leaderCardiovascular disease translational research programmeDepartment of cardiologyProgramme leaderCardiovascular research instituteBioinformatics instituteGenome institute of singaporeNovo nordisk

A*STAR, NHCS, NUS, and Novo Nordisk partner to study the mechanisms underlying heart failure

The Agency for Science, Technology and Research's Genome Institute of Singapore and Bioinformatics Institute, as well as the National Heart Centre Singapore, National University of Singapore, and pharmaceutical company Novo Nordisk have signed an agreement to study the mechanisms underlying cardiovascular disease progression-; especially the condition called heart failure with preserved ejection fraction (HFpEF).

National university of singaporeSingapore generalRoger fooMark richardsKarin conde knapeEmily hendersonChromatin organisationAgency for scienceNational heart centre singaporeFounding programme leaderCardiovascular disease translational research programmeDepartment of cardiologyProgramme leaderCardiovascular research instituteBioinformatics instituteGenome institute of singapore